Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XMT-1660 (Primary)
  • Indications Adenoid cystic carcinoma; Advanced breast cancer; Endometrial cancer; HER2 negative breast cancer; Male breast cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Mersana Therapeutics

    • Most Recent Events

    • 10 Jan 2025 According to a Mersana Therapeutics media release, company expects additional Phase 1 clinical data from dose escalation and backfill cohorts in 2025.
    • 10 Jan 2025 According to a Mersana Therapeutics media release, based on these encouraging Emi-Le data at intermediate doses, Mersana has advanced a dose of 67.4 mg/m2 every four weeks (Q4W) into an expansion cohort in patients with TNBC who have received one to four prior treatment lines, including at least one prior topo-1 ADC.
    • 10 Jan 2025 Results containing initial clinical data from first expansion cohort initiated in patients with TNBC previously treated with at least one topo-1 ADC presented in the Mersana Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top